The assessment of fracture risk with currently available clinical tools can aid the identification of patients who require further evaluation and treatment to reduce fracture risk. Optimal use of these tools requires good clinical judgment and a thorough understanding of their benefits and limitations.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
NIH Consensus Development Panel on Osteoporosis Prevention, Diagnosis, and Therapy Osteoporosis prevention, diagnosis, and therapy. JAMA 285, 785–795 (2001).
WHO Study Group. Assessment of fracture risk and its application to screening for postmenopausal osteoporosis. Report of a WHO Study Group. World Health Organ. Tech. Rep. Ser. 843, 1–129 (1994).
Baim, S. et al. Official positions of the International Society for Clinical Densitometry and executive summary of the 2007 ISCD Position Development Conference. J. Clin. Densitom. 11, 75–91 (2008).
Marshall, D. Johnell, O. & Wedel, H. Meta-analysis of how well measures of bone mineral density predict occurrence of osteoporotic fractures. BMJ 312, 1254–1259 (1996).
Wainwright, S. A. et al. Hip fracture in women without osteoporosis. J. Clin. Endocrinol. Metab. 90, 2787–2793 (2005).
Suhm, N. Lamy, O., Lippuner, K. & OsteoCare study group. Management of fragility fractures in Switzerland: results of a nationwide survey. Swiss Med. Wkly 138, 674–683 (2008).
Kanis J. A. on behalf of the World Health Organisation Scientific Group. Assessment of Osteoporosis at the Primary Health Care Level. Technical Report. Sheffield: WHO Collaborating Centre for Metabolic Bone Diseases, University of Sheffield (2007).
World Health Organization Collaborating Centre for Metabolic Bone Diseases. WHO Fracture Risk Assessment Tool [online] http://www.shef.ac.uk/FRAX/ (2009).
Lippuner, K. Johansson, H. Kanis, J. A. & Rizzoli, R. FRAX® assessment of osteoporotic fracture probability in Switzerland. Osteoporos. Int. doi:10.1007/s00198-009-0975-1.
Leslie, W. D. Tsang, J. F., Lix, L. M. & Manitoba Bone Density Program. Simplified system for absolute fracture risk assessment: clinical validation in Canadian women. J. Bone Miner. Res. 24, 353–360 (2009).
Author information
Authors and Affiliations
Ethics declarations
Competing interests
The author declares associations with the following companies: Amgen (grant/research support, scientific advisory board), Eli Lilly (grant/research support, scientific advisory board, speakers bureau), General Electric (direct stock shareholder), GlaxoSmithKline (grant/research support, scientific advisory board, speakers bureau), Novartis (grant/research support, scientific advisory board, speakers bureau), Pfizer (grant/research support), Procter & Gamble (grant/research support, direct stock shareholder), Roche (grant/research support, scientific advisory board, speakers bureau), Sanofi Aventis (grant/research support), Teva (direct stock shareholder), Upsher-Smith (scientific advisory board), Wyeth (grant/research support, scientific advisory board).
Rights and permissions
About this article
Cite this article
Lewiecki, E. Using FRAX® wisely: lessons from Switzerland and beyond. Nat Rev Endocrinol 6, 126–128 (2010). https://doi.org/10.1038/nrendo.2009.270
Issue Date:
DOI: https://doi.org/10.1038/nrendo.2009.270
This article is cited by
-
Prevalence of risk factors for fractures and use of DXA scanning in Danish women. A regional population-based study
Osteoporosis International (2011)
